

## Impact of COVID-19 pandemic on clinical care and research in Parkinson's disease

1.

**Dear PSG investigator,**

**In the midst of the current COVID-19 pandemic, the PSG seeks feedback from member investigators to determine its implications in clinical practice and research, namely the uptake of technology enabled clinical care and research.**

**The survey has two modules covering, respectively, clinical care and research**

**For purposes of this survey, face-to-face refers to the traditional evaluation which allows for a complete physical examination. Non face-to-face refers to all other forms of evaluation including telephone, synchronous and asynchronous video conferencing, wearable devices, remote monitoring and limited in home data collection (e.g. blood draw) by a trained local coordinator.**

**Please do not use your browser's back and forward button to navigate. Only use the 'Prev' and 'Next' buttons at the bottom of the page.**

## Impact of COVID-19 pandemic on clinical care and research in Parkinson's disease

### 2. CLINICAL CARE MODULE

#### BEFORE COVID-19

1. Select the modalities of non face-to-face patient-physician communication below that you used before COVID-19 to provide care to PD patients in replacement of a face-to-face clinic visit and rank them by use. The most used modality is ranked 1. If a modality was not used, please select N/A:



E-mail or other forms of secure messaging

N/A



Telephone

N/A



Video conference

N/A



Other {Please enter response in Q2 below}

N/A

2. If you selected "Other" in Q1, please specify

3. Which modalities of non face-to-face patient-physician communication were reimbursed for patient care before COVID-19? (select all options that apply)

Telephone

E-mail or other forms of secure messaging

Video conference

Not applicable

Other (please specify)

## Impact of COVID-19 pandemic on clinical care and research in Parkinson's disease

### 3. CLINICAL CARE MODULE

#### DURING COVID-19

1. Select the modalities of non face-to-face patient-physician communication below that you **NOW** use to provide care to PD patients in replacement of an face-to-face clinic visit and rank them by use. The most used modality is ranked 1. If a modality is not used, please select N/A:



Telephone

N/A



E-mail or other forms of secure messaging

N/A



Video conference

N/A



Other {Please enter response in Q2 below}

N/A

2. If you selected "Other" in Q1 above, please specify

3. Which modalities of non face-to-face patient-physician communication below are **NOW** reimbursed for patient care? (select all options that apply)

- Telephone
- E-mail or other forms of secure messaging
- Video conference
- Not applicable
- Other (please specify)

4. What type of platform have you used to conduct telemedicine (synchronous video conferencing) clinical visits? (select all options that apply)

- Institution mandated video-conference system
- Commercial video-conference system of your choice
- Smartphone video call
- Social media video call (e.g. Whatsapp, Facebook)
- N/A
- Other (please specify)

5. What platform have you used for telemedicine (synchronous video conferencing) (select all options that apply)

- Zoom
- Vidyo
- Doxy.me
- Doximity
- BlueJeans
- SBR Health/Vidyo
- V2MD by Medisprout
- Medweb
- Polycom
- WhatsApp
- Skype for business
- Cisco Jabber
- In Touch Health
- Univago
- CoviU
- American Well
- Microsoft Teams
- Google Meets
- Facebook platform
- N/A
- Other (please specify)

6. What were the most important reasons that directed you to use a particular telemedicine (synchronous video conferencing) platform? (Select your top 3 choices)

	1st choice	2nd choice	3rd choice
Institutional preference	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
HIPAA consideration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patient preference	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Provider preference	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Integration with existing electronic health records	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
N/A	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other (please specify)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Other (please specify)

7. Which barrier(s) did you encounter while using non face-to-face methods for clinical care? (select the three most important barriers and rank them by order of importance)

	1st choice	2nd choice	3rd choice
Provider resistance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patient resistance	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of access for provider	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Lack of access for patient (lack of software, camera or internet)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Institutional or practice reluctance to adopt	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
N/A	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Other (please specify)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Other (please specify)

8. For PD-related procedure visits (such as Botulinum toxin injections, DBS, Apomorphine injection or Levodopa/Carbidopa enteric infusion therapy), did you: (select all options that apply)

- Conduct visit as planned BEFORE COVID 19
- Perform remote assessments and defer procedure/device manipulation
- Cancel visit entirely
- Not applicable
- Other (please specify)

9. In which way do you see your practice change after the COVID-19 pandemic (assume current reimbursement guidelines - as per CMS or other regulatory body - remain unchanged): (select all options that apply)

Greater uptake of telemedicine (synchronous video conferencing) and fewer in-person visits

Greater use of other non face-to-face modalities such as wearables devices

No change

Other (please specify)



Impact of COVID-19 pandemic on clinical care and research in Parkinson's disease

4. CLINICAL RESEARCH MODULE

1. Are you actively involved in clinical research

- Yes
- No

## Impact of COVID-19 pandemic on clinical care and research in Parkinson's disease

### 5. CLINICAL RESEARCH MODULE

#### BEFORE COVID-19

1. Rank the modalities of non face-to-face subject-investigator communication below that you were using for scheduled clinical research visits. The most used modality is ranked 1. If a modality was not used, please select N/A.



Telephone

N/A



E-mail or other forms of secure messaging

N/A



Video conference

N/A



Other {Please enter response in Q2 below}

N/A

2. If you selected "Other" in Q1 above, please specify

## Impact of COVID-19 pandemic on clinical care and research in Parkinson's disease

### 6. CLINICAL RESEARCH MODULE

#### DURING COVID-19

1. What proportion of your research activities was suspended?

- 75 - 100%
- 50 - 74%
- < 50%
- None was suspended

2. If research activity was suspended, what were the implications? (select all options that apply)

- Furlough or lay-off research staff such as coordinators, finance managers
- Closure of the clinical research unit
- Suspend participant recruitment to studies
- Suspend start-up of new studies
- N/A
- Other (please specify)

3. If you were able to convert scheduled face-to-face clinical research assessments visits to a non face-to-face format, which modality did you use. Select and rank the applicable options. The most common modality is ranked 1. If a modality was not used, please select N/A.



Telephone

- N/A



E-mail or other forms of secure messaging

- N/A



Video conference

N/A



Remote assessment by device to collect efficacy data

N/A



Participant's home medical equipment for safety data collection

N/A



Visited participant's home to deliver study intervention or collect data

N/A



I was not able to convert

N/A



Other {Please enter response in Q4 below}

N/A

4. If you selected "Other" in Q3 above, please specify

5. If you were able to convert scheduled face-to-face clinical research assessments visits to a non face-to-face format, which of the preparatory actions did you have to do: (select all options that apply)

- Approval from sponsor and note to file
- File protocol deviation
- Filed protocol exemption from local IRB and obtained it before doing the telehealth visit/phone call
- Request IRB modification
- Train patient and caregiver to the new format
- Train staff to use new technology properly
- Not applicable
- Other (please specify)

6. If research visits needed procedures, did you: (select all options that apply)

- See patient and perform procedure as planned
- Perform remote assessments and defer procedure
- Cancel visit entirely
- Not applicable
- Other (please specify)

7. If you were able to conduct non face-to-face visits in replacement of regular face-to-face research visits, how useful were these visits in your research:

- |                       |                       |                       |                       |                       |                       |
|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Very useful           | Somewhat useful       | Minimally useful      | Neutral               | Not useful            | N/A                   |
| <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> | <input type="radio"/> |

8. Do you think non face-to-face visits may replace face-to-face research visits in the future:

- Yes
- No
- Do not know

Impact of COVID-19 pandemic on clinical care and research in Parkinson's disease

7. DEMOGRAPHICS AND CLINICAL/RESEARCH PRACTICE

1. Age group

- Under 31
- 31 - 40
- 41 - 50
- 51 - 60
- > 60

2. Years of clinical practice

- < 6
- 6 - 10
- 11 - 15
- > 15

3. Years of clinical research

- < 6
- 6 - 10
- 11 - 15
- > 15

4. Please, describe your practice: (indicate the % of dedicated time for each component below for a total of 100%)

Clinical	<input type="text"/>
Research	<input type="text"/>
Administrative	<input type="text"/>
Teaching	<input type="text"/>
Other	<input type="text"/>